Global Autoinjectors Market Report

Global Autoinjectors Market, By Type (Disposables, Reusable); By Therapy (Rheumatoid Arthritis, Diabetes, Multiple Sclerosis, Anaphylaxis, and Other Therapies), By Route of Administration (Subcutaneous, and Intramuscular); By End-Users (Homecare, Hospitals & Clinics, and Ambulatory Care Settings); By Region (North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America) Trend Analysis, Competitive Market Share & Forecast, 2017-2027

  • Published Date: May 2021
  • Report ID: BWC20334
  • Available Format: PDF
  • Page: 161

Report Overview

The Global Autoinjectors Market- Industry Trends & Forecast Report 2027

The global autoinjectors market was worth USD 44.3 billion in 2020 and is further projected to reach USD 120.2 billion by 2027, at a CAGR of 15.4% during the forecast period (2021-2027). The integration of technology with medical devices and an increasing number of targeted therapies worldwide drive the growth for autoinjectors market. Since cancer patients commonly use targeted treatments, the demand has grown as the global prevalence of cancer has increased. According to WHO, there will be 30.2 million cancer cases worldwide by 2040. In addition, the rising number of anaphylactic shock cases among anaphylaxis patients is boosting the industry.

Source: BlueWeave Consulting

 

Global Autoinjectors Overview

A syringe with a preloaded dose of medication and a spring-loaded needle are considered as autoinjectors. When the device is pressed against the body in a stabbing motion, it activates and administers a calculated dose of medication. Autoinjectors are widely used by migraine sufferers to self-administer epinephrine (to avoid anaphylaxis) and by military and emergency service personnel to counteract the effects of nerve agents. Autoinjectors have a number of advantages, including reducing the risk of needle-related phobia disorder, decreasing the risk of needle-stick injuries, maintaining dose quality accuracy, and increasing efficacy.

 

Global Autoinjectors Market Trend

Growth Drivers

Increasing Number of Technological Advancements

Technological advancements in the field of healthcare has positively impacted the market. Nowadays, auto-injectors are preferred over conventional devices as they enable efficient and improved drug delivery as well as new formulations. Technological advancements in products are also anticipated to boost growth for the market. Collaboration with top academic institutions and engineering companies to create innovatively advanced autoinjectors for patients who need them most is a key component of creating a good Research & Development (R&D) company that drives the market growth. For instance in April 2021, Teva Pharmaceutical Industries Ltd., announced the launch and availability of a new autoinjector for AJOVY. People who are suffering from four migrane days in a month can use AJOVY. It is a subcutaneous medication used to avoid migraine attacks in adults. It was only available in prefilled syringes when it was first introduced in 2020, but now AJOVY is available in two formats: autoinjectors and prefilled syringes.

Growing Prevalence of Targeted Therapies

Targeted therapy is a type of cancer treatment in which specific proteins and genes are targeted using specified drugs that are involved in cancer cell growth and survival. Targeted therapy can alter the tissue environment that promotes cancer growth and survival, or it can target cancer-related cells like blood vessel cells. Doctors nowadays frequently combine targeted therapy with chemotherapy and other treatments. The Food and Drug Administration (FDA) of the United States has also approved targeted therapies for a variety of cancers. Autoinjectors are used to kill particular cells in the body for this targeted therapy.

According to The World Health Organization, in 2020, there were 19.3 million cancer cases. The number of cases is expected to reach 30.2 million by 2040. Men are more likely to develop lung, prostate, colorectal, stomach, and liver cancers, while women are more likely to develop breast, colorectal, lung, cervical, and thyroid cancers. The market is also expected to benefit from the rising demand for successful targeted therapies procedures for cancer.

Restraints

Alternative Drug Delivery Model

The majority of patients experience pain and find it inconvenient to administer medication through syringes or other conventional methods. Since autoinjectors may be painful in some cases, new or alternative drug delivery models are used to treat the condition. Nasal, oral, and topical drug delivery are examples of alternative drug delivery models. These alternative drug delivery models are low-cost, reliable, and widely embraced by patients due to their convenience. According to a 2019 study published in the Journal of Advanced Study, most children are afraid of needles, with 20-50 % of adolescents and 20-30% of adults having this fear. As previously reported, the fear of needles and the adoption of new drug delivery models are limiting the market growth for autoinjectors.

Impact of COVID-19

COVID-19 has had a negative impact on the supply chain in a variety of industries. When the economies of various countries were reviving, some of them were hit by the second wave of the COVID-19 pandemic. COVID-19 has wreaked havoc on countries such as India and Brazil. The deadly virus has had an impact on several industries, including automotive, chemical, oil and gas, pharmaceuticals, construction and building, and others. However, some sectors of the pharmaceutical industry are growing. As the autoinjectors market has grown significantly in the year 2020, most of the patients found it challenging to go to the hospital in the fear of contracting the virus. Furthermore, as technology advances, patients are finding it more convenient to use autoinjectors at home.

Global Autoinjectors Market: By Type

Based on type, the global autoinjectors market is grouped into disposable and reusable. In 2020, the disposable segment accounted for the largest share in the autoinjectors market by applications segment. Patients are increasingly using disposable autoinjectors because they are cost-effective, easy to use, have built-in glass syringes, and are convenient. Furthermore, disposable autoinjectors contribute to less disease spread. In addition, the rising advancement for biodegradable disposable autoinjectors further drives the market for autoinjectors market.

 

Source: BlueWeave Consulting

 

Global Autoinjectors Market: By End-Users

End-users divide the global autoinjectors market into three categories: homecare, hospitals & clinics, and ambulatory care settings. The homecare settings accounted for the largest share in the market in 2020. The large share of this end-user segment can be attributed primarily to the rapid growth of the global geriatric population and the growing need for cost-effective drug administration. The geriatric population has grown significantly in recent years, owing to the fact that geriatric populations are more susceptible to disease. Furthermore, the growing number of diabetic patients worldwide fuels market growth for autoinjectors.

Global Autoinjectors Market: Regional Insights

Geographically, the global autoinjectors market is categorized into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. North America accounted for the largest share in the market in 2020. The North American region is the leading global autoinjector market followed by the Asia-Pacific. According to the Asthma and Allergy Foundation America, more than 50 million Americans suffer from allergies of various kinds. Furthermore, allergies are the sixth leading cause of chronic disease in the United States. Because of the rising prevalence of allergies in the United States, there has been an increase in anaphylactic shock, resulting in an increase in the use of autoinjectors in this region.

Competitive Landscape

Some of the key players include AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceutical, Antares Pharma, Merck KGaA, and other prominent players. In order to achieve competitive share in the market key players are collaborating with research institutes for the development of advanced autoinjectors.

Recent Development

·         In April 2021, Teva Pharmaceutical Industries Ltd., announced the launch and availability of a new autoinjector for AJOVY. The product is now available in two latex-free1 formats— a new autoinjector and a prefilled syringe.

·         In 2020, BD (Becton, Dickson and Company), a leading global medical technology company published the results of a 52-subject human-based clinical trial on the BD wearable injector.

 

Scope of the Report

Attribute

Details

Years Considered

Historical data – 2017-2020

Base Year – 2020

Forecast – 2021 – 2027

Facts Covered

Revenue in USD Billion

Market Coverage

U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Argentina, Japan, South Korea, Australia, China, India, UAE, South Africa, Saudi Arabia, Turkey

Product/Service Segmentation

By type, route of administration, therapy, end-user and region

Key Players

Key Players for the market are AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceutical, Antares Pharma, Merck KGaA, and other prominent players

 

 

 

By Type

Ø  Disposable

Ø  Reusable

By Therapy

Ø  Rheumatoid Arthritis

Ø  Diabetes

Ø  Multiple Sclerosis

Ø  Anaphylaxis

Ø  Other Therapies

By Route of Administration

Ø  Subcutaneous

Ø  Intramuscular

By End-Users

Ø  Homecare

Ø  Hospitals & Clinics

Ø  Ambulatory Care Settings

By Region

Ø  The Asia-Pacific

Ø  North America

Ø  Europe

Ø  The Middle East & Africa

Ø  Latin America

 

FAQs:

1.    What is the current size of the global autoinjectors market?

Answer: The global autoinjectors market has reached USD 44.3 billion in 2020.

 

2.    What are the major factors driving the growth of the global autoinjectors market?

Answer:  The major factors driving the growth of the global autoinjectors market are the increasing number of technological advancements and growing prevalence of targeted therapies.

3.    Who are the key players in the global autoinjectors market?

Answer:  The key players in the global autoinjectors market are AbbVie Inc., Mylan, Eli Lilly and Company, Ypsomed, Amgen, Becton, Dickinson and Company, GlaxoSmithKline plc, Johnson & Johnson, Teva Pharmaceutical, Antares Pharma, Merck KGaA, and other prominent players.

4.    Which type accounted for the larger share in the global autoinjectors market?

Answer:  Based on product, the disposable segment accounted for the larger share in the global autoinjectors market.

5.    Which region is growing at a higher rate in the global autoinjectors market?

Answer: The Asia-Pacific region is growing at a higher rate in the global autoinjectors market.